Obefazimod

Phase 2

Abivax S.A. (ABVX)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

ABVXPhase 2$7.8B

Obefazimod Phase 2 Est. Readout

Obefazimod• Moderately to Severely Active Crohn Disease212

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Moderately to Severely Active Crohn Disease

View Full Landscape

Drug Information

Target Indication

Moderately to Severely Active Crohn Disease

Clinical Trial

NCT06456593

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ABVX

Abivax S.A.

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

ABX464Phase 3

Ulcerative Colitis

ABX203 therapeutic Hepatitis B vaccine treatment armPhase 3

Chronic Hepatitis B

ABX196Phase 2

Carcinoma, Hepatocellular

ABX464 50mgPhase 2

Rheumatoid Arthritis

ABX464 100 mgPhase 2

Ulcerative Colitis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts